(NECN) - The field of targeted therapies based on genetic indicators.
The goal: A second look at drugs that did not make the cut for treating the general population, but do work for very specific patients.
Newton, Massachusetts-based Clinical Data is a case in point.
President and CEO Drew Fromkin joins Business Day with more information.
Play video
